Quarterly ResultMay 14, 2026, 07:37 AM
Karyopharm Q1 Total Revenue $35.1M; Endometrial Cancer Trial Enrollment Complete
AI Summary
Karyopharm Therapeutics Inc. reported first-quarter 2026 financial results, with total revenue reaching $35.1 million and U.S. XPOVIO net product revenue at $29.2 million. The company announced the completion of enrollment for its Phase 3 XPORT-EC-042 trial in endometrial cancer, with topline data anticipated in mid-2026. Additionally, results from the Phase 3 SENTRY trial in myelofibrosis were selected for a late-breaking oral presentation at ASCO. Karyopharm reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million.
Key Highlights
- Q1 2026 Total Revenue was $35.1 million, up from $30.0 million in Q1 2025.
- Q1 2026 U.S. XPOVIO Net Product Revenue was $29.2 million, up from $21.1 million in Q1 2025.
- Net loss for Q1 2026 improved to $22.4 million ($1.02/share) from $23.5 million ($2.77/share) in Q1 2025.
- Completed enrollment of Phase 3 XPORT-EC-042 trial in endometrial cancer; topline data expected mid-2026.
- Phase 3 SENTRY trial results in myelofibrosis accepted for late-breaking oral presentation at ASCO on June 2.
- Reaffirmed full-year 2026 total revenue guidance of $130 million to $150 million.
- Cash, cash equivalents, and restricted cash totaled $91.2 million as of March 31, 2026.
- Existing liquidity is expected to fund current operating plans into late Q3 2026.